Reuters logo
BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​
November 14, 2017 / 9:15 PM / 3 days ago

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

Nov 14 (Reuters) - Acceleron Pharma Inc

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

* Acceleron Pharma - ‍ Preclinical results show potential first-in-class disease-modifying properties of sotatercept in pulmonary arterial hypertension​

* Acceleron Pharma Inc - ‍Expects to initiate a phase 2 trial in 1H 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below